ribupatide vs tirzepatide

NCT06396429 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT04184622 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial in 2,539 participants using percent change in body weight, the disease-defining endpoint for obesity, as the primary measure. All three tirzepatide doses produced significantly greater weight loss than placebo at 72 weeks.

NCT06649344 · Phase 3 · completed

Randomized, open-label phase 3 comparing once-weekly ribupatide against semaglutide as add-on to metformin in type 2 diabetes (884 participants). The design is randomized and actively controlled but unblinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT03730662 · Phase 3 · completed

The study randomized 2,002 participants to tirzepatide or active insulin glargine control, but treatment was open-label rather than blinded. The primary endpoint was change in HbA1c, a laboratory surrogate rather than a hard clinical outcome; although the primary comparisons were statistically significant in favor of tirzepatide, this supports a moderate evidence grade.